Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network

BACKGROUND: The European Medicine Agency granted marketing approval to 164 orphan medicinal products for rare diseases, among which 28 products intended for the treatment of hereditary metabolic diseases. Taking advantage of its privileged connection with 69 healthcare centres of excellence in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Heard, Jean-Michel, Vrinten, Charlotte, Schlander, Michael, Bellettato, Cinzia Maria, van Lingen, Corine, Scarpa, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945588/
https://www.ncbi.nlm.nih.gov/pubmed/31907071
http://dx.doi.org/10.1186/s13023-019-1280-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945588/
https://www.ncbi.nlm.nih.gov/pubmed/31907071
http://dx.doi.org/10.1186/s13023-019-1280-5

Ejemplares similares